News

August 9, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the 2004 recall of one...

July 29, 2011 — Boston Scientific Corporation's board of directors has approved a five-year, $150 million investment to expand its commercial presence in China, one of the world's largest and...

July 27, 2011 – Micell Technologies Inc. announced that it has completed patient enrollment in its DESSOLVE II CE mark clinical study of the MiStent drug-eluting coronary stent system. The MiStent...

July 26, 2011 – The Resolute drug-eluting stent (DES) from Medtronic Inc. showed superiority to Boston Scientific Corp.’s Taxus DES on in-stent late lumen loss at eight months, the primary...

June 30, 2011 — Micell Technologies Inc. announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the...
Cordis announced it will cease production of the Cypher sirolimus-eluting stent, the first drug-eluting stent (DES) to secure U.S. Food and Drug Administration (FDA) approval, by the end of 2011. The...
June 3, 2011 – New long-term data from the DIVERGE study, presented at EuroPCR 2011, showed that the use of the Axxess drug-eluting stent (DES) for the treatment of complex coronary bifurcation...
May 25, 2011 – Boston Scientific Corp. today announced it received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25 mm Promus everolimus-eluting coronary stent system for...
The U.S. Food and Drug Administration (FDA) cleared the Xience nano everolimus-eluting coronary stent system for the treatment of coronary artery disease in small vessels. The Xience nano, which is...
May 23, 2011 — Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its...
May 23, 2011– A pooled analysis of the global Resolute clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute...
May 20, 2011 - Boston Scientific Corporation today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25mm Promus...
May 20, 2011 – e-BioMatrix post-marketing surveillance (PMS) registry information presented at EuroPCR 2011 has confirmed that BioMatrix, Biosensors’ Biolimus A9-eluting stent system with abluminal...
May 16, 2011 – In a coronary stent patent lawsuit, a jury said Cordis owes Boston Scientific approximately $19.5 million.
May 11, 2011 - Micell Technologies announced that positive preclinical data will be presented at the EuroPCR conference regarding the MiStent Drug-Eluting Coronary Stent System (MiStent DES), an...

April 26, 2011 – The U.S. Food and Drug Administration (FDA) announced this week it cleared Boston Scientific’s Ion paclitaxel-eluting coronary stent system. 

The stent, available for...

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in...

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led...

April 8, 2011 — A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to coronary artery bypass surgery (CABG) in patients with...

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College of Cardiology (ACC) Scientific Session in New Orleans. The trial compared the...